missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human GPR17 (aa 329-367) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (92%), Rat (92%). This recombinant protein control fragment may be used for blocking experiments. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The G-protein-coupled receptor (GPCR) superfamily is comprised of an estimated 600-1,000 members and is the largest known class of molecular targets with proven therapeutic value. GPR17 is an orphan G protein-coupled receptor involved in orchestration of oligodendrocyte differentiation and myelination in the central nervous system. GPR17 is expressed in brain, kidney, heart and umbilical vein endothelial cells. GPR17 has dual specificity for uracil nucleotides and cysteinyl leukotrienes and signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and cysteinyl leukotrienes following ischemia.
Specifications
Specifications
| Accession Number | Q13304 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 2840 |
| Name | Human GPR17 (aa 329-367) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AI853548; DKFZp686M18273; G protein-coupled receptor 17; Gpr17; gpr17 {ECO:0000312; G-protein coupled receptor 17; P2Y-like receptor; R12; RGD:1589785}; UDP/CysLT receptor; Uracil nucleotide/cysteinyl leukotriene receptor; Y12546; Z94155 |
| Common Name | GPR17 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction